Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices

Background

Patients with extensive-stage small cell lung cancer (ES-SCLC) treated with chemotherapy frequently experience chemotherapy-induced myelosuppression (CIM), leading to reduced production of white blood cells, red blood cells (RBCs), and/or platelets. Among patients with ES-SCLC treated with chemotherapy at Florida Cancer Specialists & Research Institute (FCS) community oncology clinics, prevalence of grade ≥3 CIM episodes in ≥1 or ≥2 lineages was 62.1% or 33.9%, respectively.¹ This study evaluated CIM outcomes of patients with ES-SCLC treated with trilaciclib during chemotherapy at FCS clinics.

Methods

The retrospective cohort study identified adults treated with trilaciclib during chemotherapy for ES-SCLC between February 1, 2021–May 15, 2022 in FCS structured electronic medical records. Patients in clinical trials or with <14 days follow-up (except death) were excluded. Descriptive statistics were reported for prevalence of CIM episodes by type (anemia, thrombocytopenia, neutropenia) and grade across all chemotherapy cycles with trilaciclib. CIM episodes included events within 21 days from the start of a treatment cycle with trilaciclib administration.

Results

Patients treated with trilaciclib (N=50) were, on average, 67.8 years old, 56.0% female, and 56.0% White. During follow-up (median=2.7 months), 42.0% of patients had a grade ≥3 CIM episode in ≥1 lineage (anemia: grade 3=18.0%; thrombocytopenia: grade 3=20.0%, grade 4=6.0%; neutropenia: grade 3=24.0%, grade 4=4.0%). Grade ≥3 CIM episodes in ≥2 lineages occurred in 18.0% of patients. Supportive care utilization (eligibility for RBC or platelet transfusion, granulocyte colony-stimulating factor use, erythropoiesis-stimulating agents use, intravenous hydration) will also be reported.

Conclusions

Early real-world outcomes following treatment with trilaciclib suggest a potential for reductions in CIM among patients with ES-SCLC. Future studies are required to confirm the findings.

Disclosures

This study was funded by G1 Therapeutics, Inc. L. Lopez-Gonzalez and H. Huang are employees of G1 Therapeutics, Inc. L.Hart, K. Boykin, R. Bailey, T. Heritage, and L. Gordan are employees of the Florida Cancer Specialists & Research Institute, which received funding from G1 Therapeutics, Inc., for this work. A. Ogbonnaya and K. Deyoung are employees of Xcenda, which received funding from G1 Therapeutics, Inc., for this work.